In Reply We appreciate the feedback from Drs Strandberg and Tarkkanen. Our study’s conclusion of association between statin use and cataract diagnosis was questioned because our outcome was based on medical records rather than a standardized diagnostic protocol. We agree that randomized clinical trials (RCTs) that use standardized diagnostic protocols are preferable to studies using medical records databases. Despite being the gold standard in determining efficacy of medications, RCTs have limitations in assessing adverse events (AEs).1 Randomized clinical trials are usually only powered to detect efficacy, not AEs. They may exclude those individuals at greatest risk for AEs and have excluded as many as 30% of those screened for the study.2 Withdrawal from trials also may result in an underestimation of AEs; an average of 10% of patients drop out from studies, and these patients are potentially those with the most significant AEs.2 Additionally, RCTs are typically shorter and may be prematurely terminated once benefits are documented.1 Despite their rigorousness, RCTs of statins are not devoid of bias3 and potential conflict of interest for their sponsors.4 Sometimes RCTs use questionnaires to collect information, but patients’ surveys may be biased owing to selective nonresponse.5
Mansi I, Leuschen J, Mortensen EM. Cataracts and Statin Use—Reply. JAMA Ophthalmol. 2014;132(3):365–366. doi:10.1001/jamaophthalmol.2014.75
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.